- 中文名稱
Atezolizumab 生物類似藥, 人 PD-L1 單克隆抗體
- 英文名字
- Atezolizumab Biosimilar, Human PD-L1 Monoclonal Antibody
- 供應商
- Promab
- 產品貨號
- PMB-B00018
- 產品報價
- ￥詢價/1mg/5mg/20mg
- 產品說明書
- 點擊查看
- 購買方式
- 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868
- 產品新聞
- 背景資料
- What is Atezolizumab biosimilar research grade? Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab. Atezolizumab lacks the N-glycosylation site in its Fc region by changing an aspartic acid into alanine at amino acid position 298 (amino acid position 297 according to EU nomenclature, N297A) in the heavy chain leading to minimized binding to FcγRs.nnPD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Atezolizumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
- 應用類型
- Flow cytometry, animal model study
- 免疫原
- Human PD-L1
- 來源宿主
- CHO cells
- 反應性
- Human
- 保存建議
- Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
- 其他
- ProMab 生物技術公司通過整合生物信息學、分子生物學、蛋白質表達、純化技術、基因克隆、微生物學和免疫學，利用新型高通量技術開發重組蛋白、抗體和工程細胞系并將其商業化。專注于免疫治療領域，特別是 CAR-T/NK 細胞技術。ProMab 還開發了一種新型的 mRNA 脂質納米顆粒（mRNA-LNP）平臺，用于即用型試劑和定制研究服務，以推進現有產品并擴展到更多的研究領域。
- 注意
-
該頁面的中文產品信息的翻譯，僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前，請瀏覽說明書確認。
-
